Alvotech

Research Alvotech (ALVO) on Bullrun: market cap USD 1.23B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALVO
• ExchangeNASDAQ
• CountryLuxembourg
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Market capUSD 1.23B
• Financial periodQ1 2026
• RevenueUSD 105.87M
• Net incomeUSD 1.03M
• Free cash flow-USD 106.62M
• Gross margin56.5%

Valuation Snapshot

latest market cap is USD 1.23B.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications;

Frequently asked questions

What is Alvotech's market cap?

Alvotech's market capitalization is USD 1.23B.

What does Alvotech do?

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.